Basophil activation test in a case of systemic hypersensitivity reaction to infliximab with good tolerance to another anti-TNF-α agent (adalimumab)

Journal of Investigational Allergology and Clinical Immunology

Volumn 20, Issue 6, 2010, Pages 537-538

  Manso, L ^a   Polo, B ^a   Fernandez Nieto M ^a,b   Sastre, B ^a,b   del Pozo, V ^a,b   Sastre, J ^a,b  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Adalimumab; Basophil activation test (BAT); Drug allergy; Infliximab; Systemic hypersensitivity reaction

Indexed keywords

ADALIMUMAB; ADRENALIN; AZATHIOPRINE; DEXCHLORPHENIRAMINE; INFLIXIMAB; METHYLPREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ARTICLE; BASOPHIL ACTIVATION TEST; CASE REPORT; CONTINUOUS INFUSION; CROHN DISEASE; DRUG HYPERSENSITIVITY; DRUG TOLERANCE; DRUG WITHDRAWAL; FLUSHING; FOLLOW UP; HEART PALPITATION; HOSPITAL DISCHARGE; HUMAN; IMMUNE FUNCTION TEST; INTRACUTANEOUS TEST; MALAISE; MALE; PRICK TEST; PRURITUS; REPEATED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN TEST; URTICARIA;

ADULT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DRUG HYPERSENSITIVITY; HUMANS; MALE; SKIN TESTS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78650107021     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Köhler G, Millstein C. Continuous cultures of fused cells secreting antibody of predefined specifity. Nature. 1975; 256:495-7.
2. Vergara G, Silvestre J F, Betlloch I, Vela P, Albares M P, Pascual JC. Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern. Arch Dermatol. 2002; 138:1258-9.
3. Sugiura F, Kojima T, Oba M, Tsuchiya H, Ishiguro N. Anaphylactic reaction to infliximab in two rheumatoid arthritis patients who had previously received infliximab and resumed. Mod Rheumatol. 2005; 15:201-3.
4. Chávez-López MA, Delgado-Villafaña J, Gallaga A, Huerta-Yáñez G. Severe anaphylactic reaction during the second infusion of infliximab in a patient with psoriatic arthritis. Allergol Immunopathol (Madr) 2005; 33:291-2.
5. Benucci M, Manfredi M, Demoly P, Campi P. Injection site reactions to TNF-a blocking agents with positive skin tests. Allergy. 2008; 63:138-9.
6. Brennan PJ, Bouza TR, Hsu FI, Sloane DE, Castells MC. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol. 2009; 124(6):1259-66.
7. Manso L, Heili S, Fernández-Nieto M, Sastre B, Sastre J. Basophil activation in two cases of hydrochlorothiazide-induced noncardiogenic pulmonary edema. Allergy. 2010; 65:135-6.
8. Baudouin V, Cusiak A, Hadad E, Schandene L, Goldman M, Loirat C, Abramowicz D. Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti-interlekin-2-receptor monoclonal antibody basiliximab. Transplantation. 2003; 76:459-63.
9. Domm A. A patient's reaction to infl iximab. Ann Allergy Asthma Immunol. 2003; 90:298-301.
10. Stallmach A, Giese T, Schmidt C, Meuer SC, Zeuzem SS. Severe anaphylactic reaction to infliximab: successful treatment with adalimumab - report of a case. Eur J Gastroenterol Hepatol. 2004; 16:627-30.